Literature DB >> 30790547

In Vivo Confocal Microscopy Demonstrates Increased Immune Cell Densities in Corneal Graft Rejection Correlating With Signs and Symptoms.

Chareenun Chirapapaisan1, Alessandro Abbouda2, Arsia Jamali3, Rodrigo T Müller3, Bernardo M Cavalcanti1, Clara Colon1, Deborah Witkin1, Afsun Sahin2, Reza Dana1, Andrea Cruzat1, Pedram Hamrah4.   

Abstract

PURPOSE: Diagnosis of graft rejection is based on patient symptoms and on clinical signs detected by slit-lamp biomicroscopy. This study investigated whether laser in vivo confocal microscopy (IVCM) can aid in the diagnosis of corneal graft rejection by detecting cellular corneal changes that take place after transplantation.
DESIGN: Prospective case-control study.
SUBJECTS: Thirty-eight eyes of 38 patients with penetrating keratoplasty (15 eyes with corneal graft rejection, 23 eyes without rejection) and 9 age-matched normal controls.
METHODS: Laser IVCM was performed in the corneal grafts centrally. The density of immune cells (IC) was assessed for epithelial, sub-epithelial, stromal, and endothelial layers by 2 masked observers. IC density was compared among different groups and correlated to clinical signs and symptoms of corneal graft rejection. MAIN OUTCOME MEASUREMENTS: Outcome measurement was the IC density in the corneal layers and its associations with the presence of clinical signs and symptoms of corneal graft rejection.
RESULTS: The IC density was significantly different between rejected and non-rejected grafts (P = 0.004) and different from that of normal controls (P = 0.001). Among corneal layers, IC density was significantly higher in rejected grafts than in non-rejected grafts in only the sub-basal (611.54 ± 573.74 vs. 340.61 ± 268.60 cells/mm2, respectively; P = 0.049) and endothelial layers (250.62 ± 267.13 vs. 103.47 ± 81.91 cells/mm2, respectively; P = 0.001). Patients with decreased best corrected visual acuity, Khodadoust line, and anterior chamber cells demonstrated a significant increase in total IC density (P < 0.05), whereas patients with symptoms of irritation, light sensitivity, and pain revealed a specific increase in IC density in the sub-basal layer (P < 0.05). Patients with ocular pain had higher IC density in the epithelial layer than those without pain (P = 0.03).
CONCLUSIONS: Patients with corneal graft rejection demonstrate a significant increase in corneal immune cells, particularly, in the sub-basal and endothelial layers compared to patients with non-rejected grafts and controls. Although symptoms associated with endothelial rejection demonstrate a general increase in IC, pain, irritation, and light sensitivity are associated with increased IC in the sub-basal layer. Assessment of patients with corneal graft rejection by IVCM may serve as an adjunctive tool in the diagnosis and management of corneal graft rejection.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30790547     DOI: 10.1016/j.ajo.2019.02.013

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

Review 1.  Advances in corneal graft rejection.

Authors:  Jia Yin
Journal:  Curr Opin Ophthalmol       Date:  2021-07-01       Impact factor: 4.299

2.  Characteristics of Corneal Subbasal Nerves in Different Age Groups: An in vivo Confocal Microscopic Analysis.

Authors:  Chareenun Chirapapaisan; Sittiphong Thongsuwan; Niphon Chirapapaisan; Pratuangsri Chonpimai; Anupong Veeraburinon
Journal:  Clin Ophthalmol       Date:  2021-08-24

3.  In vivo Confocal Microscopic Evaluation of Corneal Changes in Acute Endothelial Rejection.

Authors:  Golshan Latifi; Ramon Katoozpour; Reza Ghaffari; Parisa Abdi; Maryam Kasiri; Sahar Berijani
Journal:  J Curr Ophthalmol       Date:  2021-10-22

Review 4.  Variable Responses to Corneal Grafts: Insights from Immunology and Systems Biology.

Authors:  Antonio Di Zazzo; Sang-Mok Lee; Jaemyoung Sung; Matteo Niutta; Marco Coassin; Alireza Mashaghi; Takenori Inomata
Journal:  J Clin Med       Date:  2020-02-21       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.